Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Clinical results of implantation of the new sinusoidal trifocal IOL

Search Title by author or title

Session Details

Session Title: New IOLs: Material & Preload IOL

Session Date/Time: Monday 24/09/2018 | 08:00-10:30

Paper Time: 08:33

Venue: Room A3, Podium 2

First Author: : P.Stodulka CZECH REPUBLIC

Co Author(s): :                        

Abstract Details


First 3 months experience with new trifocal intraocular lens for cataract surgery or refractive lens exchange.


Gemini Eye Clinics, Czech Republic


Laser assisted (Victus, B+L) cataract surgery was performed on 20 eyes of 20 patients with cataract or hyperopia. New trifocal sinusoidal IOL Acriva Trinova (VSY Biotechnology) were implanted. This lens unlike the traditional diffractive trifocal IOLs has no sharp edges at its anterior optical surface. UDVA, CDVA, UIVA, CIVA, UNVA, CNVA, defocus curve and contrast sensitivity were assessed. A trifocal FineVison Micro F (Physiol) lenses were implanted to the fellow eye of our patients.


All surgeries were uneventful. Sinusoidal IOL distance results: mean UDVA improved from 0,8 logMAR preop. to 0,1 logMAR 3 months postop.; mean CDVA improved from 0,23 logMAR preop. to 0,01 logMAR 3 months postop.; mean distance refraction was -0,1 D sf. eq. 3 months postop. Sinusoidal IOL near results: mean UNVA improved from J 12 preop. to J 2; mean CNVA was J 1 both preop. and 3 months postop. Defocus curves showed visual acuities ≥ 0,3 logMAR throughout defocus interval -3 to +0,5D for both trifocal IOL types. Patient satisfaction questionnaire results were similar for both IOLs.


First clinical results with 3 months follow up of new sinusoidal trifocal IOL are promising. Both trifocal technologies provided similar clinical results. Longer follow up and data from more patients are required for further evaluation of this new technology.

Financial Disclosure:


Back to previous